A Safety, Pharmacokinetic and Pharmacodynamic Study of

New Post Public Reply Private Reply Replies (0) Message Board
BigJeff

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

Summary

In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important
role in protecting the body. p53 functions by activating proteins that repair DNA and kill
cells that have genetic mutations such as in cancers. Research experiments showed that when
cancer cells were treated with Kevetrin, it activated p53 which induced p21, a protein that
inhibits cancer cell growth. p53 also induced PUMA (p53 up-regulated modulator of
apoptosis), a protein that causes tumor cell death. Because of these activities, slowing
cancer cell growth and causing cancer cell death, Kevetrin may help to treat tumors.

Description

Kevetrin was found to be effective in pre-clinical studies of human xenograft tumor models
and was reasonably well-tolerated at therapeutic doses in the non-clinical animal studies.
Kevetrin was also effective in multi-drug resistant tumor models; therefore, Kevetrin has
the potential to treat tumors that have become resistant to standard chemotherapy. This
trial will determine tolerance in humans and, possibly, efficacy with a Phase I, open-label,
dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of Kevetrin, in adult
patients with solid tumors.

The primary objectives are the following:

- To determine the maximum tolerated dose (MTD) of Kevetrin.

- To determine the dose limiting toxicities (DLT) of Kevetrin.

- To establish a safe dose level of Kevetrin that can be used for future studies.

The secondary objectives are to determine the following:

- The pharmacokinetics of Kevetrin in humans.

- Observe for evidence of antitumor activity following administration of Kevetrin.

- If Kevetrin induces changes in the biomarker p21 in peripheral blood lymphocytes.

- If there is a pharmacodynamic relationship between the plasma concentrations of
Kevetrin and a clinical or cellular effect.

During each 4 week cycle, each patient will receive three weekly doses of Kevetrin given as
a 1 hour intravenous infusion followed by a 1 week off-treatment period. Following each
dose, each patient will be monitored. If the patients have acceptable safety and tolerance,
Kevetrin will be given once weekly for a total of 3 weeks. During each cycle patients will
be evaluated for safety, tolerance, and Dose-Limiting Toxicity (DLT) that occur during a
cycle.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Solid Tumors

Intervention

thioureidobutyronitrile

Location

Dana-Farber / Harvard Cancer Center
Boston
Massachusetts
United States
02215

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 35

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 83

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 80

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 5

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 55

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 92

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading

Top 5 Most Recently Viewed Articles

Donnette Irving Takes Charge of Navis Pack & Ship Atlanta

Updated Category News Views 179

Donnette Irving Takes Charge of Navis Pack & Ship Atlanta Annex Brands, Inc. is expanding its presence in the oversized freight shipping and crating sector through recent developments at the Navis Pack & Ship location in Atlanta. The transition of ownership marks an exciting new chapter for the established franchise, now led by Donnette Irving, who is determined to uphold...

Continue Reading
Impact of EU’s Urban Wastewater Directive on Finland’s Pharmaceutical Industry

Updated Category News Views 175

Understanding the EU’s Urban Wastewater Treatment Directive The newly enforced Urban Wastewater Treatment Directive by the EU, effective from January 1, 2025, carries significant implications for various industries, particularly pharmaceuticals. This directive requires manufacturers in the pharmaceutical, cosmetics, and hygiene sectors to take charge of the costs...

Continue Reading
Innovations in OpenTelemetry Transform Digital Resilience for Businesses

Updated Category News Views 200

Enhancing Observability with OpenTelemetry Innovations New observability innovations empower organizations to apply OpenTelemetry to large-scale environments with complete business visibility Splunk, the cybersecurity and observability leader, has unveiled groundbreaking innovations designed to improve the OpenTelemetry experience. These advancements equip organizations...

Continue Reading
Abeona Therapeutics Expands Workforce with New Stock Grants

Updated Category News Views 158

Abeona Therapeutics Enhances Employee Inducement Programs Abeona Therapeutics Inc. has recently made significant strides in its workforce development by offering new equity awards to non-executive employees who joined the company. This move aligns with the company's commitment to fostering a dynamic work environment and was sanctioned under Nasdaq Listing Rule 5635(c)(4)....

Continue Reading
MIND Technology, Inc. Achieves Impressive Fiscal Growth

Updated Category News Views 190

MIND Technology, Inc. Reports Strong Fiscal Growth in Fourth Quarter MIND Technology, Inc. (NASDAQ: MIND), a leading provider of technology solutions for marine industries, recently revealed its financial performance for the fourth quarter and year-end results. The company reported noteworthy revenues, highlighting impressive growth compared to previous quarters. Revenue...

Continue Reading